A Phase I Study of Allogeneic Natural Killer Cell Therapy Generated from Cord Blood Hematopoietic Stem and Progenitor Cells in Elderly Acute Myeloid Leukemia Patients
Harry Dolstra(Radboud University Nijmegen), Nicolaas Schaap(Radboud University Nijmegen), Jos Paardekooper(Radboud University Nijmegen), Anniek B. van der Waart(Radboud University Nijmegen), Aniek de Graaf(Radboud University Nijmegen), Peter E. Westerweel(Albert Schweitzer Ziekenhuis), Joop H. Jansen(Radboud University Nijmegen), Gerwin Huls(University Medical Center Groningen), Mieke W.H. Roeven(Radboud University Nijmegen), Bert A. van der Reijden(Radboud University Nijmegen), Carel Trilsbeek(Radboud University Nijmegen), Jan J. Cornelissen(Erasmus MC), Jan Spanholtz(AIMM Therapeutics (Netherlands)), Marleen Tordoir(Radboud University Nijmegen), Nicole M. A. Blijlevens(Radboud University Nijmegen), Fenna Bohme(AIMM Therapeutics (Netherlands)), Gerard M.J. Bos(Maastricht University), Tjeerd J.F. Snijders(Medisch Spectrum Twente), Frank Preijers, Frans Maas(Radboud University Nijmegen), Marij Leenders(Radboud University Nijmegen), Hans Pruijt(Jeroen Bosch Ziekenhuis), Arnold van der Meer(Radboud University Nijmegen), Jeannette Cany, Nina Kok(AIMM Therapeutics (Netherlands)), Basav N. Hangalapura(Radboud University Nijmegen)
Cited by 7
Related Papers
Hyperhomocysteinemia as a Risk Factor for Deep-Vein Thrombosis
|New England Journal of Medicine|1996|1.1k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714